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Abstract 
Background: c-Myc has been proposed as a putative target gene of signal transducer and activator of transcription 
5 (STAT5). No functional STAT5 binding site has been identified so far within the c-Myc gene locus, therefore a direct 
transcriptional regulation by STAT5 remains uncertain. c-Myc super-enhancer, located 1.7 Mb downstream of the 
c-Myc gene locus, was recently reported as essential for the regulation of c-Myc gene expression by hematopoietic 
transcription factors and bromodomain and extra-terminal (BET) proteins and for leukemia maintenance. c-Myc super-
enhancer is composed of five regulatory regions (E1–E5) which recruit transcription and chromatin-associated factors, 
mediating chromatin looping and interaction with the c-Myc promoter.
Results: We now show that STAT5 strongly binds to c-Myc super-enhancer regions E3 and E4, both in normal and 
transformed Ba/F3 cells. We also found that the BET protein bromodomain-containing protein 2 (BRD2), a co-factor of 
STAT5, co-localizes with STAT5 at E3/E4 in Ba/F3 cells transformed by the constitutively active STAT5-1*6 mutant, but 
not in non-transformed Ba/F3 cells. BRD2 binding at E3/E4 coincides with c-Myc transcriptional activation and is lost 
upon treatment with deacetylase and BET inhibitors, both of which inhibit STAT5 transcriptional activity and c-Myc 
gene expression.
Conclusions: Our data suggest that constitutive STAT5 binding to c-Myc super-enhancer might contribute to BRD2 
maintenance and thus allow sustained expression of c-Myc in Ba/F3 cells transformed by STAT5-1*6.
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Background
c-Myc is a master regulator of essential biological pro-
cesses such as cell proliferation, survival, differen-
tiation, metabolism, angiogenesis and pluripotency 
establishment and maintenance [1, 2]. c-Myc is found 
overexpressed in most human cancers and is a hallmark 
of tumor initiation and maintenance [3, 4]. Characteriz-
ing the regulatory mechanisms of c-Myc gene expression 
is therefore fundamental for a better understanding of 
its deregulation in cancer and to possibly identify novel 
therapies aiming at controlling its expression. c-Myc 
gene transcription is regulated by multiple transcription 
factors via responsive elements located within both its 
promoter and remote enhancer regions [1, 5–9]. A num-
ber of reports, including those from our lab, provided 
evidence that c-Myc expression is regulated by signal 
transducer and activator of transcription 5 (STAT5) [10–
13]. STAT5 is an essential regulator of cell differentiation, 
proliferation and survival [11, 14, 15] and is frequently 
constitutively activated in cancer. STAT5 constitutive 
activation results in c-Myc overexpression, increased cell 
proliferation and reduced cell apoptosis, and is as such an 
important player in cancer initiation and progression [11, 
16–20]. Among molecules that suppress STAT5 activity, 
inhibitors of tyrosine kinases, of deacetylases and of bro-
modomain and extra-terminal (BET) proteins represent 
promising therapeutic agents, either alone or in combi-
nation [21–28]. We and others showed that expression 
Open Access
BMC Molecular Biology
*Correspondence:  anne.rascle@klinik.uni-regensburg.de 
†Sophia Pinz and Samy Unser contributed equally to this work
Stat5 Signaling Research Group, Institute of Immunology, University 
of Regensburg, 93053 Regensburg, Germany
Page 2 of 11Pinz et al. BMC Molecular Biol  (2016) 17:10 
of STAT5 target genes, including c-Myc, is reduced upon 
treatment with deacetylase inhibitors (trichostatin A, 
suberoylanilide hydroxamic acid, apicidin, valproic acid, 
sodium butyrate) or with the BET inhibitor (+)-JQ1 
[12, 29–31]. Further elucidating the process of STAT5-
induced expression of c-Myc and of its inhibition by clini-
cally relevant therapeutic agents is critical for improving 
cancer therapy.
Among the evidence of a direct regulation of c-Myc by 
STAT5, an elegant study by Lord et al. demonstrated that 
c-Myc expression in response to IL-2 and IL-3 is depend-
ent on the transactivation domain of STAT5 [10]. Accord-
ingly, c-Myc expression is upregulated in cells expressing 
constitutively active STAT5, including in the BCR-ABL-
transformed human leukemic cell line K562 [11–13, 32]. 
Constitutive activation of STAT5 by the oncogenic tyros-
ine kinase BCR-ABL contributes to K562 cell transfor-
mation [33, 34]. Overexpression of c-Myc in K562 cells 
is inhibited by the BCR-ABL tyrosine kinase inhibitor 
imatinib but also by the deacetylase inhibitor trichostatin 
A (TSA), which we showed to inhibit STAT5-mediated 
transcription [12, 31, 32]. In the same line, overexpres-
sion of c-Myc in Ba/F3 cells expressing the constitutively 
active STAT5 mutant 1*6 [35] is repressed by TSA [12, 
31]. In apparent contradiction with a direct regulation 
a c-Myc by STAT5, we found that STAT5 knock-down 
in Ba/F3 cells did not affect IL-3-induced c-Myc gene 
expression [13]. Two other acknowledged direct target 
genes of STAT5, Bcl-x and Id-1 [10, 13, 36–38], remained 
equally unaffected upon STAT5 knock-down in Ba/F3 
cells [13]. Although these observations might be inter-
preted as an indication that these genes are not regulated 
by STAT5, they might also reflect an unconventional 
mechanism of regulation by STAT5, possibly not as sen-
sitive to the partial (60  %) knock-down generated upon 
siRNA transfection [13]. Interestingly, in contrast to most 
classical STAT5 target genes (e.g., Cis, Osm, Spi2.1, …) 
which display STAT5 responsive elements within their 
promoter region [13], functional STAT5 binding sites 
have been identified outside the promoter regions of Bcl-
x and Id-1, notably within Bcl-x first intron [36, 38] and 
within Id-1 enhancer located several kb downstream of 
the Id-1 gene [37]. These observations raise the possibil-
ity that regulation of c-Myc expression by STAT5 might 
be likewise unconventional, possibly involving distal 
elements. In support of this proposition, we previously 
attempted and failed to detect STAT5 binding along the 
c-Myc gene [13], including at GAS elements present in its 
promoter and known to mediate transcriptional response 
to other STAT family members [39–41].
Recently, several research groups described the role 
of a 3′ super-enhancer in the regulation of c-Myc gene 
expression in hematopoietic cells and its importance in 
c-Myc overexpression in leukemic cells [5–8, 42]. c-Myc 
super-enhancer is located 1.7  Mb downstream of the c-
Myc coding region. It consists of five enhancer regions 
(E1–E5) with multiple binding sites for transcription fac-
tors. These transcription factors recruit transcriptional 
co-factors, in particular the BET bromodomain protein 
BRD4 and the SwItch/Sucrose non-fermentable (SWI/
SNF) protein BRG1. These chromatin-associated fac-
tors mediate c-Myc transcription via long-range chro-
matin looping and selective interaction with the c-Myc 
promoter [5–7]. On the other hand, we recently demon-
strated that STAT5 transcriptional activity is regulated by 
BET proteins, including BRD2 [31]. We found that BRD2 
is recruited along STAT5 at the proximal promoter and 
transcription start site of the conventional STAT5 tar-
get gene Cis, both upon IL-3-induced STAT5 activation 
and in cells expressing and transformed by constitutively 
active STAT5. BRD2 association with the Cis gene is lost 
upon treatment with the BET inhibitor (+)-JQ1 (there-
after referred to as JQ1 [43]), resulting in transcriptional 
inhibition [31]. Interestingly, deacetylase inhibitors also 
repress STAT5-mediated transcription by displacing 
BRD2 and preventing recruitment of the transcriptional 
machinery [12, 31]. Our data therefore suggest that 
STAT5 recruits BRD2 which, in turn, supports transcrip-
tional activation by assisting the assembly of the pre-
initiation complex [12, 31]. Given that STAT5-induced 
expression of c-Myc is also inhibited by JQ1 [30, 31, 44], 
and given the absence of STAT5 binding activity within 
c-Myc promoter and gene locus, we tested the hypothesis 
that STAT5 binds to the 3′ super-enhancer and recruits 
BRD2 proteins to regulate c-Myc gene expression.
Results
c‑Myc expression is induced by STAT5 and repressed 
by inhibitors of deacetylases and of BET proteins in Ba/
F3‑derived cells
This study was conducted in the mouse IL-3-dependent 
pro-B cell line Ba/F3 [45] and in its transformed IL-3-in-
dependent counterpart Ba/F3-1*6, which expresses the 
constitutively active mutant STAT5A-1*6 [35]. Whereas 
STAT5 phosphorylation, binding to DNA and tran-
scriptional activity are induced by IL-3 in Ba/F3 and Ba/
F3-WT cells, they are constitutive in Ba/F3-1*6 cells in 
the absence of IL-3 (Fig.  1a, b and [11, 12, 29, 31, 35]), 
hence mimicking the situation found in cancer cells. As 
such, Ba/F3 (or Ba/F3-WT) and Ba/F3-1*6 cells represent 
ideal experimental models to study and compare STAT5-
mediated transcription in normal and cancer cells 
respectively. Similarly to that of the STAT5 target genes 
Cis and Osm [12, 31], expression of c-Myc was induced 
by IL-3 in cells expressing wild-type STAT5 while it was 
upregulated in cells expressing the STAT5A-1*6 mutant 
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Fig. 1 c-Myc gene expression in Ba/F3-derived cell lines. a STAT5 protein and phosphorylation levels in the parental Ba/F3 cells and in Ba/F3 cells 
stably expressing STAT5A-WT (Ba/F3-WT) and STAT5A-1*6 (Ba/F3-1*6). Ba/F3 and Ba/F3-WT cells, which grow in IL-3-containing medium, were 
withdrawn from IL-3 for 11 h and stimulated with IL-3 for 15 min. IL-3-independent Ba/F3-1*6 cells were stimulated with IL-3 in parallel. Brij whole-
cell protein lysates (20 μg) were analysed by Western blot using antibodies specific for phosphorylated STAT5 (pSTAT5), total STAT5A and STAT5B 
(STAT5A/B), transgenic STAT5A-WT and STAT5A-1*6 (FLAG), and α-tubulin as a loading control. STAT5A/B signal in parental Ba/F3 cells corresponds 
to endogenous STAT5 protein levels, while the signals detected in the stable cell lines Ba/F3-WT and Ba/F3-1*6 represent both endogenous (STAT5A 
and STAT5B) and transgenic (STAT5A-WT or -1*6) proteins. b STAT5-mediated expression of c-Myc in Ba/F3-WT and -1*6 cells. Rested Ba/F3-WT cells 
stably expressing wild-type STAT5A were pre-treated 30 min with 200 nM TSA and further stimulated with IL-3 for 30 min. Ba/F3-1*6 cells expressing 
constitutively active STAT5A-1*6 were treated in parallel with 200 nM TSA for 60 min. Expression of STAT5 target genes (Cis, Osm, c-Myc) and of the 
housekeeping gene 36b4 was analysed by RT-qPCR. Expression of c-Myc, like that of Cis and Osm, was induced by STAT5A-WT and by constitutively 
active STAT5A-1*6, in an IL-3-dependent and -independent manner respectively. STAT5A-WT- and STAT5A-1*6-mediated expression of c-Myc, Cis 
and Osm was inhibited by the deacetylase inhibitor trichostatin A (TSA). Student’s t tests were employed to compare on the one hand IL-3-induced 
(WT) or 1*6-induced gene expression to the unstimulated WT control, and on the other hand TSA-treated to the vehicle control in each condition; 
**P < 0.01, ***P < 0.001, ****P < 0.0001; a P value <0.05 was considered statistically significant. c Expression of STAT5 target genes is inhibited by 
both deacetylase (TSA) and BET (JQ1) inhibitors. Ba/F3 cells were pre-treated with 20 nM TSA or 500 nM JQ1 for 30 min and stimulated with IL-3 for 
60 min. Expression of STAT5 target genes (Cis, c-Myc) and of control genes (IL-3-dependent MAPK target gene JunB and housekeeping gene 36b4) 
was analysed by RT-qPCR, as above. IL-3-induced expression of Cis and c-Myc, but not that of JunB, was inhibited by TSA and JQ1. One-way ANOVA 
with Dunnett’s multiple comparison test was used to assess differences between TSA- or JQ1-treated conditions and the vehicle-treated IL-3-stimu-
lated control; ***P < 0.001; a P < 0.05 was considered statistically significant
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in the absence of IL-3 (Fig. 1b). In both cell lines, expres-
sion of Cis, Osm and c-Myc was inhibited by the deacety-
lase inhibitor trichostatin A (TSA) (Fig. 1b), in agreement 
with our previous reports that deacetylase inhibitors 
(notably TSA, valproic acid, apicidin, sodium butyrate 
and clinically relevant SAHA) prevent STAT5-mediated 
transcription [12, 31]. Likewise, STAT5-mediated expres-
sion of Cis and c-Myc in Ba/F3 cells was inhibited by the 
BET inhibitor JQ1 (Fig.  1c), as already reported [6, 30, 
31, 44]. Expression of the IL-3-inducible but STAT5-
independent gene JunB was not inhibited by TSA or JQ1 
(Fig. 1c) while expression of the housekeeping gene 36b4 
remained unaffected in all conditions (Fig. 1b, c).
STAT5 binds to c‑Myc super‑enhancer
Ba/F3 and Ba/F3-1*6 cells were used to investigate tran-
scription factor recruitment along the c-Myc gene locus 
in normal and STAT5-transformed cells respectively. 
Chromatin immunoprecipitation (ChIP) assays were 
conducted in Ba/F3 and Ba/F3-1*6 cells using STAT5-
specific antibodies. Immunoprecipitated genomic DNA 
was analysed by quantitative PCR using primers spe-
cific for the c-Myc gene locus—including known STAT 
binding sites—and for its 3′ super-enhancer (E1 to E5). 
Primers specific for regions encompassing the STAT5 
binding sites of the Cis and Osm genes were investigated 
as controls (Fig. 2a). Upon IL-3 stimulation of Ba/F3 cells, 
STAT5 was specifically detected at the STAT5 binding 
sites present within the proximal promoter of the Cis and 
Osm genes (Fig. 2b). With the exception of a very weak 
STAT5 binding at a previously described STAT1 binding 
site within c-Myc promoter [40], no STAT5 binding was 
detected within the c-Myc locus. By contrast, a strong 
signal was detected specifically at the E3 and E4 regions 
of c-Myc super-enhancer (Fig.  2b). Interestingly, a simi-
lar binding pattern was found in Ba/F3-1*6 cells (Fig. 2c), 
demonstrating that both IL-3-induced wild-type STAT5 
and constitutively activated STAT5-1*6 bind to c-Myc 
super-enhancer elements E3 and E4. In support of STAT5 
binding to E3 and E4, sequence analysis of the c-Myc 
super-enhancer revealed the presence of clusters of puta-
tive STAT5 binding sites within E3 and E4, both consen-
sus (TTCNNNGAA) and non-consensus [46], conserved 
between mouse and human genomes at the same posi-
tion (Fig. 3). No conserved putative STAT5 binding sites 
were identified within E1, E2 and E5 (not shown).
BRD2 co‑localizes with constitutively active STAT5 at c‑Myc 
super‑enhancer
Given that BRD4 is recruited at c-Myc super-enhancer 
in hematopoietic and leukemic cells [5, 6], and since we 
recently showed the implication of BRD2 in STAT5-
mediated transcription in Ba/F3 and Ba/F3-1*6 cells [31], 
we investigated the recruitment of BRD2 along the c-Myc 
gene and super-enhancer by chromatin immunoprecipi-
tation (Fig.  4). In cells expressing STAT5A-1*6, BRD2 
bound at E3 and E4, but not at E1, E2 and E5 of c-Myc 
super-enhancer (Fig.  4a). Unexpectedly, BRD2 was also 
detected at the reported STAT1 binding site within the 
c-Myc promoter. As previously described [31], BRD2 was 
found proximate to the transcription start site of the Cis 
gene (Fig.  4a). BRD2 binding at Cis and c-Myc was lost 
upon treatment with the BET inhibitor JQ1 (Fig.  4a), 
demonstrating BRD2 binding specificity. Interestingly, 
BRD2 binding was reduced at Cis transcription start site 
and abolished at c-Myc E3/E4 upon TSA treatment, but 
not at the c-Myc promoter (STAT1) location. We previ-
ously showed that TSA-induced inhibition of STAT5 
transcriptional activity correlates with BRD2 loss at the 
STAT5 target gene Cis [31]. We therefore show here that, 
similarly, BRD2 binding at E3/E4—but not at STAT1 ele-
ment within its promoter—along with STAT5, strictly 
correlates with c-Myc transcriptional activation. Our data 
thus strongly suggest that BRD2 association with c-Myc 
super-enhancer is involved in STAT5-mediated tran-
scription of c-Myc. The presence of BRD2 around the 
STAT1 binding site and its insensitivity to TSA, suggest 
that BRD2 is recruited in a STAT5-independent man-
ner to the c-Myc promoter, possibly by other transcrip-
tion factors [5–7], and that BRD2 association at this site 
is not implicated in STAT5-mediated transcription of the 
c-Myc gene.
To better characterize the role of STAT5 in BRD2 
recruitment to STAT5 target genes, we next addressed 
whether STAT5A-1*6 and BRD2 physically interact. 
Co-immunoprecipitation experiments were carried out 
on nuclear lysates from formaldehyde-crosslinked Ba/
F3-1*6 cells using STAT5A- and BRD2-specific antibod-
ies and following the ChIP protocol (Additional file  1: 
Fig. S1A–C). Upon immunoprecipitation (IP), sam-
ples were analysed by Western blot (Additional file  1: 
Fig. S1B) and quantitative PCR as a control (Additional 
file 1: Fig. S1C). Recruitment efficiency and specificity of 
STAT5A-1*6 and BRD2 to the Cis gene was comparable 
to that observed before (Additional file 1: Fig. S1C). No 
co-immunoprecipitation of STAT5A-1*6 and BRD2 was 
detected in Western blot, following neither STAT5A nor 
BRD2 IP (Additional file 1: Fig. S1B). It should be noted 
that, while STAT5A was strongly immunoprecipitated 
under the ChIP experimental conditions, BRD2 was 
poorly pulled-down in the same conditions (Additional 
file 1: Fig. S1B), probably explaining the weak signals usu-
ally detected by qPCR following BRD2 ChIP (Additional 
file  1: Fig. S1C; Fig.  4a), but also making it difficult to 
evidence a co-immunoprecipitation with STAT5A. The 
weak immunoprecipitation efficiency observed in BRD2 
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Fig. 2 STAT5 specifically binds to the E3 and E4 regions of c-Myc super-enhancer. a Schematic representation of the mouse STAT5 target genes Cis, 
Osm and c-Myc and of the qPCR amplicons analysed following chromatin immunoprecipitation. Nucleotide positions are relative to the respective 
transcription start sites (TSS). Functional STAT binding sites within the individual promoter regions are indicated as grey bars. P1 and P2 desig-
nate c-Myc dual promoters, P2 being predominant in normal cells. E1 to E5 symbolise the five domains of c-Myc 3′ super-enhancer. Black boxes 
underneath the respective genes represent the qPCR amplicons. Primers amplifying regions within Cis and c-Myc open reading frame (ORF) were 
used as controls. b Chromatin immunoprecipitation (ChIP) was performed with whole-cell lysates from Ba/F3 cells (conventional ChIP protocol), 
either unstimulated or stimulated 30 min with IL-3, using antibodies specific for STAT5A + STAT5B (STAT5 ChIP). Immunoprecipitated genomic 
DNA (gDNA) was analysed by qPCR using primers shown in a. One-way ANOVA with Dunnett’s post test was used to evaluate IL-3-induced STAT5 
enrichment at the various loci compared to the signal detected at the c-Myc “ORF” region, used as a reference and background control; ***P < 0.001; 
a P < 0.05 was considered statistically significant. c ChIP was conducted with nuclear lysates (alternative ChIP protocol) from Ba/F3-1*6 cells grown 
in the absence of IL-3, using antibodies specific for STAT5A, which recognize STAT5A-1*6 mutant. Immunoprecipitated gDNA was analysed by qPCR, 
as in b. One-way ANOVA with Dunnett’s multiple comparison test was used to evaluate STAT5 enrichment at the various loci vs. c-Myc “ORF” region, 
used as a reference and background control; *P < 0.05, ***P < 0.001
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ChIP is likely the consequence of the experimental con-
ditions used (formaldehyde-mediated crosslinking and/
or IP buffer composition). Indeed, conventional immu-
noprecipitation from nuclear lysates of non-crosslinked 
cells (Additional file  1: Fig. S1D) and using mild buffer 
conditions resulted in efficient BRD2 immunopre-
cipitation (Additional file  1: Fig. S1E). However, no co-
immunoprecipitation of STAT5A was observed in these 
conditions. Altogether, these experiments suggest that 
STAT5A-1*6 and BRD2 do not directly interact but are 
rather co-recruited at the chromatin level.
Finally, we investigated BRD2 association with the c-
Myc gene and its super-enhancer in IL-3-stimulated Ba/
F3 cells. While BRD2 was recruited upon IL-3 stimula-
tion at the transcription start site of the Cis gene, as 
previously described [31], no BRD2 enrichment above 
the IgG background was detected along the c-Myc 
gene and downstream enhancer in the same conditions 
(Fig.  4b). This observation suggests that, by contrast to 
STAT5A-1*6, IL-3-induced wild-type STAT5 might not 
be efficient in recruiting and/or stabilizing BRD2 at c-
Myc enhancer.
Discussion
This study identified functional STAT5 binding sites pos-
sibly regulating c-Myc transcription. We showed that 
STAT5 specifically binds to enhancer regions E3 and E4 
of c-Myc 3′ super-enhancer. Putative STAT5 binding sites 
within E3/E4 are organised in clusters of consensus and 
non-consensus binding motifs. Similar functional STAT5 
binding sites have been described at other STAT5 target 
genes [13]. Binding of wild-type STAT5 to E3/E4 was 
induced by IL-3 in normal Ba/F3 cells while STAT5A-1*6 
binding was constitutive and independent of IL-3 in 
transformed Ba/F3-1*6 cells. Interestingly, ChIP-Seq 
assays performed in human HEL leukemia cells revealed 
that JAK2V617F-induced constitutive active STAT5 [47, 
48] is bound at c-Myc enhancer region E3 (ArrayExpress 
c-Myc - E3
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h TCTGGGTTTTCTGAAACTATGTGATTTGCCATGAGGTTCACAGAGAGTTTA
m TCTGGGTTGTCTGAAACCATGTGATTTGACACGAGGTTAACCGAGAGTTTA
Fig. 3 Sequence alignment of the mouse and human enhancer regions E3 and E4 located 3′ of the c-Myc gene. Consensus STAT5 binding sites 
(TTCNNNGAA) that are conserved between mouse and human sequences are designated as white boxes. Non-consensus STAT5 binding sites (usu-
ally TTCNNNNAA or TTNNNNGAA) are underlined [46]. E3 and E4 contain each one consensus and a cluster of 8–9 non-consensus putative STAT5 
binding motifs that are well-conserved in both mouse and human genomes at the same position. Such pattern of conserved motifs was absent 
from E1, E2 and E5 elements (not shown)
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accession number E-MTAB-1096; [49]), providing 
another evidence of STAT5 constitutive binding at c-Myc 
super-enhancer in leukemia cells.
Constitutive binding of STAT5 at E3/E4 in Ba/F3-1*6 
cells coincided with that of BRD2, suggesting that STAT5 
might play a role in BRD2 maintenance at c-Myc super-
enhancer in transformed cells. By contrast, BRD2 was not 
detected by ChIP at the c-Myc locus in IL-3-stimulated 
Ba/F3 cells. We cannot exclude at this point that this 
absence of specific signal is due to a detection problem. 
Alternatively, it might be the consequence of transient 
STAT5 binding in Ba/F3 cells, as opposed to constitutive 
STAT5 binding in Ba/F3-1*6 cells which might be neces-
sary for BRD2 maintenance at c-Myc super-enhancer. We 
could not evidence an interaction between STAT5A-1*6 
and BRD2 in co-immunoprecipitation assays. Therefore, 
our data suggest that constitutive binding of STAT5A-1*6 
at E3/E4 might—directly or indirectly—assist and/or sta-
bilize BRD2 association with c-Myc super-enhancer. Fur-
thermore, it remains possible that other BET protein(s) 
are involved in the regulation of c-Myc by wild-type 
STAT5 in Ba/F3 cells. This proposition is supported by 
our previous observation that BRD2 was detected at the 
Cis but not at the Osm promoter in IL-3-stimulated Ba/
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Fig. 4 BRD2 co-localizes with STAT5 at E3/E4 in Ba/F3 cells transformed by constitutive active STAT5A-1*6. a Ba/F3-1*6 cells were treated for 60 min 
with 200 nM TSA, 1 μM JQ1 or 0.02 % DMSO (vehicle). Nuclei isolation and ChIP was performed following the alternative protocol, and using 
BRD2-specific antibodies or the same amount of rabbit IgG as a control. qPCR primers are depicted in Fig. 2a. Only the vehicle-treated IgG control 
is shown. TSA- and JQ1-treated IgG controls exhibited similar background levels (data not shown), as previously reported [31]. BRD2 binds strongly 
to the Cis transcription start site (TSS), the c-Myc promoter region (STAT1) and enhancer regions E3 and E4. BRD2 association is lost upon JQ1 treat-
ment and is reduced at Cis TSS and c-Myc E3/E4 upon treatment with the deacetylase inhibitor TSA. Background cut-off (horizontal line) was defined 
as the mean of the signal generated by the IgG negative controls plus 2x the standard deviation (SD) of the IgG control (mean IgG + 2x SD). BRD2 
enrichment at the various loci in the vehicle-treated condition was evaluated using One-way ANOVA with Dunnett’s multiple comparison vs. c-Myc 
“ORF” region, used as a reference; of note, BRD2 signal intensity at the c-Myc “ORF” region is not reduced upon JQ1 treatment, suggesting that it 
corresponds to background BRD2 signal; **P < 0.01, ***P < 0.001; a P < 0.05 was considered statistically significant. One-way ANOVA with Dunnett’s 
post test was used to assess differences between TSA- or JQ1-treated conditions and the vehicle-treated control; ##P < 0.01, ###P < 0.001; a P < 0.05 
was considered statistically significant. b Ba/F3 cells were stimulated with IL-3 for 30 min and BRD2 ChIP was conducted with whole-cell lysates 
using BRD2-specific antibodies or rabbit IgG, following the conventional ChIP protocol [12, 31]. Genomic DNA was analysed as in a. Only back-
ground signals were detected along the c-Myc gene locus and downstream super-enhancer in Ba/F3 cells, while BRD2 was recruited in response 
to IL-3 at the transcription start site (TSS) of the Cis gene. Background cut-off (horizontal line) was defined as described in A (mean IgG + 2x SD). 
Student’s t test was used to monitor IL-3-induced BRD2 recruitment at Cis TSS; **P < 0.01; a P < 0.05 was considered statistically significant
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F3 cells [31]. This is also in agreement with the impli-
cation of BRD4 in long-range regulation of c-Myc tran-
scription via its 3′ super-enhancer [5, 6]. Interestingly, it 
was shown that multiple transcription factors, the BET 
protein BRD4 and the SWI/SNF component BRG1 are 
recruited to c-Myc 3′ enhancer and contribute to c-Myc 
gene transcription [5, 6]. Notably, BRG1 was proposed to 
maintain transcription factor occupancy at the enhancer 
region and to facilitate interactions with the c-Myc pro-
moter [5]. Whether such a mechanism of stabilisation by 
BRG1 also takes place in STAT5-mediated transcription 
remains to be shown. Maintenance of STAT5 occupancy 
at c-Myc super-enhancer would be an attractive explana-
tion for the absence of effect of STAT5 (partial) knock-
down on c-Myc gene expression [13].
Conclusions
We showed that constitutive binding of STAT5 and 
maintenance of BRD2 at E3/E4 in transformed Ba/F3-1*6 
cells correlated with transcriptional activation of c-Myc. 
Furthermore, BRD2 binding at E3/E4 was lost upon 
TSA- and JQ1-mediated inhibition of c-Myc expression, 
both of which inhibit STAT5-induced transcription [31]. 
Our data therefore suggest that constitutive binding of 
STAT5A-1*6 contributes to BRD2 maintenance at c-Myc 
super-enhancer in transformed Ba/F3-1*6 cells, which 
in turn might be implicated in c-Myc overexpression. 
In support of a role of STAT5 in c-Myc overexpression 
in leukemia via c-Myc super-enhancer, E3 was recently 
shown to display enhancer activity in K562 leukemia 
cells, using a luciferase reporter assay [5]. This finding 
nicely fits with our previous finding that c-Myc expres-
sion in K562 cells is dependent on BCR-ABL-induced 
constitutive active STAT5 [32]. Our model is hence in 
line with the recently suggested leukemia maintenance 
function attributed to c-Myc 3′ super-enhancer, via the 
recruitment of BET proteins by hematopoietic transcrip-
tion factors [5, 6, 8]. We propose that the transcription 
factor STAT5 might play a similar role in c-Myc over-
expression, in leukemia exhibiting constitutive STAT5 
activation. Further functional assays will be necessary to 
verify this proposition.
Methods
Chemicals
Dimethyl sulfoxide (DMSO) and trichostatin A (TSA) 
were purchased from SIGMA (D-2650 and T-8552 
respectively). (+)-JQ1 (BPS Bioscience #27401)—hereaf-
ter abbreviated to JQ1—was purchased from BIOMOL 
GmbH. TSA and JQ1 were dissolved in DMSO at a final 
concentration of 1 mM (TSA) and 5 mM (JQ1). DMSO 
was used as vehicle control. Its final concentration was 
adjusted to 0.02 % in all conditions.
Cells
All cell lines were cultivated at 37 °C under 5 % CO2 in a 
humidified incubator. The interleukin-3 (IL-3)-dependent 
mouse pro-B cell line Ba/F3 (a kind gift from Jacqueline 
Marvel, IFR 128 BioSciences Gerland-Lyon Sud, France 
[45]) was grown in RPMI 1640 (PAN-Biotech P04-16500) 
supplemented with 10 % heat-inactivated fetal calf serum 
(FCS; PAN-Biotech), penicillin/streptomycin (100  U/mL 
penicillin, 100  μg/mL streptomycin; PAN-Biotech) and 
2 ng/ml rmIL-3 (ImmunoTools). No ethical approval was 
required to obtain and use the Ba/F3 parental cell line. Ba/
F3-derived cell lines were generated according to German 
GenTSV (genetic engineering safety regulations; authori-
zation AZ.55.1-8791.7.52). The IL-3-independent Ba/
F3-1*6 cell line (clone F7) stably expressing the FLAG-
tagged constitutively active mouse STAT5A-1*6 mutant 
[35] has been described [32], and was grown in RPMI 1640 
supplemented with 10 % heat-inactivated FCS, penicillin/
streptomycin and 600 μg/ml G418 (SIGMA A-1720). The 
IL-3-dependent Ba/F3-WT cell line (clone A7) expressing 
FLAG-tagged wild-type (WT) mouse STAT5A was gener-
ated by electroporating Ba/F3 cells with a pcDNA3-based 
expression vector allowing expression of a mSTAT5A-WT-
FLAG fusion protein. Stably transfected cells were selected 
in IL-3-containing medium in the presence of 800 μg/mL 
G418 (PAA). Individual clones were isolated and charac-
terized to verify mSTAT5A-WT transgene expression and 
proper IL-3-dependent activation of STAT5A-WT. Ba/
F3-WT clone A7 was used for this study and served as a 
control for potential adverse effects of FLAG-tagged pro-
tein overexpression. Ba/F3-WT cells were maintained in 
RPMI 1640 supplemented with 10 % heat-inactivated FCS, 
penicillin/streptomycin, 600 μg/ml G418 (SIGMA A-1720) 
and 2  ng/ml rmIL-3. For cytokine stimulation of Ba/F3 
and Ba/F3-WT cells, cells were washed twice in RPMI 
1640 and rested in RPMI 1640, 10 % FCS, penicillin/strep-
tomycin for 6–12  h before addition of 5  ng/ml IL-3 for 
15–120 min, as indicated. For inhibitor treatment of Ba/F3 
and Ba/F3-WT cells, rested cells were pre-treated 30 min 
with the respective compound or with DMSO (vehicle) 
prior to IL-3 stimulation. Ba/F3-1*6 cells were treated with 
inhibitors or vehicle for 60 min.
For co-immunoprecipitation assays from non-
crosslinked cells, previously described Ba/F3-tet-on-1*6 
cells conditionally expressing STAT5A-1*6 in the pres-
ence of doxycycline were used [31]. Briefly, Ba/F3-tet-
on-1*6 cells were grown for 9 h in the presence of 1 μg/ml 
doxycycline in IL-3-free medium. Cells were harvested 
for nuclear fractionation and western blot analysis.
Gene expression analysis by RT‑qPCR
Following inhibitor and cytokine treatments, cells were 
harvested, cDNA synthesized and quantitative PCR 
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performed as previously described [31]. Nucleotide 
sequence of the qPCR primers used in this study have 
been published [12, 13, 31]. Data were normalized to 
mouse S9 ribosomal mRNA and expressed as relative 
mRNA levels, like previously reported [12, 31]. Data are 
mean ± SD of the quantitative PCR performed in either 
duplicate or triplicate, and are representative of at least 
two independent experiments.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) was carried 
out from either whole-cell (conventional protocol) or 
nuclear (alternative protocol) lysates, following reported 
procedures [12, 31, 50]. Chromatin Immunoprecipita-
tion from nuclear lysates yields stronger signals than 
from whole cell lysates [50]. Antibodies used were as 
follows: STAT5A (Santa Cruz Biotechnology sc-1081), 
STAT5A + B (Santa Cruz Biotechnology sc-835), BRD2 
(Bethyl A302-583A) and IgG from rabbit serum (SIGMA 
I-5006). Antibody concentrations used were as reported 
[12, 31]. Co-precipitated genomic DNA was measured 
by quantitative PCR. Mouse Cis- and Osm-specific prim-
ers have been described [31]. Mouse c-Myc-specific 
forward and reverse primers were the following, respec-
tively: STAT1, TTTATTCTAGGGTCTCTGCAGGC and 
GAAAACCCGGACTTCCCAG; STAT3, CCCTCCTGC 
CTCCTGAAGG and CAGGATCCCTCCCCTCCC; 
ORF, AACAACCGCAAGTGCTCCAG and GTCGTTT 
TCCTCCGTGTCTGAG; E1, ACGCTCAGAGTGCTT 
TCCAT and GGTGGTGTGGGGTGACTAATAT; E2, 
GTGGGAGGGACTGAAATGGAG and TGGGCAAAG 
CTAGAGGCAGAT; E3, GAACAGGAAGCTGGGGAA 
AT and TGCAAGGAGGCTTTTCCTAA; E4, CACCCC 
AGCCTCAATTCAGT and GCTGCGATGACTT 
CTAAACGG; E5, GCAACAGCAAGAACCAGTGA and 
TGCTTCTCCTGAACCACCTT. Results are expressed 
as percentage (%) of input DNA. Data are mean  ±  SD 
of the quantitative PCR performed in either duplicate 
or triplicate, and are representative of at least two inde-
pendent experiments.
Protein analysis by immunoprecipitation and Western blot
Western blots were performed as described [32], using 
the following antibodies and respective dilutions: 
pSTAT5 (#9351, Cell Signaling Technology; 1:1000), 
STAT5A (L-20, sc-1081, Santa-Cruz Biotechnology; 
1:1000), STAT5A/B (C-17, sc-835, Santa-Cruz Biotech-
nology; 1:1000), FLAG (M2, SIGMA F-1804; 1:500), 
Brd2 (Bethyl A302–583A; 1:2000), α-tubulin (DM1A, 
sc-32293, Santa-Cruz Biotechnology; 1:200), HDAC1 
(Millipore 05-100; 1:1000), Anti-Rabbit IgG-Peroxidase 
(SIGMA A0545; 1:10,000), Anti-Mouse IgG-Peroxidase 
(SIGMA A8924; 1:10,000). HDAC1 and α-tubulin were 
used as nuclear and cytosolic protein markers respec-
tively to control the quality of the nuclear fractionation, 
like previously reported [31].
Brij whole-cell protein lysis and nuclear fractionation 
from non-crosslinked cells were conducted as previously 
described [31]. Immunoprecipitations from non-crosslinked 
Ba/F3-tet-on-1*6 cells was performed using 250 μg nuclear 
protein lysate diluted 1:10 in Brij buffer (10 mM Tris–HCl 
pH 7.5, 150 mM NaCl, 2 mM EDTA pH 8.0, 0.875 % Brij 
97, 0.125 % NP40, 10 mM NaF, 1 mM Na3VO4, 10 μg/ml 
leupeptin, 10 μg/ml aprotinin, 0.5 mM phenylmethylsulfo-
nyl fluoride) and 1.2 μg BRD2 antibody (Bethyl A302–583A) 
or 1.2 μg rabbit IgG (SIGMA I-5006) as a negative control. 
Immunoprecipitations were conducted for 5 h and immu-
nocomplexes were collected using protein A-Sepharose 
beads. Consecutive to washing in Brij buffer, beads were 
boiled in 60 μl Laemmli buffer. Half of the eluted bead frac-
tion was analyzed by Western blot in parallel to input lysate 
(3  % or 8  μg nuclear proteins) and immunoprecipitation 
supernatants (same volume as input lysate).
Nuclear-enriched protein lysate preparation and immu-
noprecipitations (IP) from formaldehyde-crosslinked Ba/
F3-1*6 cells were carried out following the alternative 
ChIP protocol described above [31, 50], using 7  ×  106 
cells for the nuclei preparation and 2.4 μg antibody (rab-
bit IgG, STAT5A or BRD2) per IP. Subsequent to the last 
washing step, ~20  % beads were further processed for 
genomic DNA isolation and qPCR analysis, following the 
ChIP protocol. The remaining beads were boiled 10 min 
in 50  μl Laemmli buffer and ~40  % of the eluted bead 
fraction (20 μl) was analysed by Western blot in parallel 
to input lysate (3 %) and immunoprecipitation superna-
tants (same volume as input lysate).
Additional file
Additional file 1: Fig. S1. Protein interaction between STAT5A-1*6 and 
BRD2 cannot be evidenced in co-immunoprecipitation assays. Nuclear 
lysates from formaldehyde-crosslinked (A-C) or non-crosslinked (D, E) 
STAT5A-1*6-expressing cells were prepared as described in the Methods 
section. Nuclear protein enrichment was verified by Western blot using 
antibodies specific for the nuclear and cytosolic proteins HDAC1 and 
α-tubulin respectively, and STAT5A-1*6 expression was monitored using 
the FLAG antibody (A, D). Immunoprecipitations (IP) were performed as 
described in the “Methods” section using the indicated antibodies. Input 
(In), immunoprecipitation supernatants (SN) and eluted bead fractions 
(B) were analysed by immunoblot (IB) using the indicated antibodies (B, 
E). In panel B, arrow points to BRD2 and (*) indicates a non-specific signal 
associated with the bead fractions. Bead samples from the IP experiment 
shown in panel B (crosslinked cells) were further processed for ChIP 
analysis by qPCR, using the Cis-specific primers depicted in Fig. 2a (C). 
In panel C, background cut-off (dotted line) was defined as in legend to 
Fig. 4 (mean IgG background + 2x SD). One-way ANOVA with Dunnett’s 
multiple comparison test was used to evaluate BRD2 and STAT5 enrich-
ment at the STAT5 binding site (STAT5) and transcription start site (TSS) of 
the Cis gene, in comparison to the “ORF” region, used as a reference and 
background control; ***P < 0.001; a P value < 0.05 was considered statisti-
cally significant.
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